Dabocemagene autoficel is under clinical development by Castle Creek Biosciences and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Dabocemagene autoficel’s likelihood of approval (LoA) and phase transition for Epidermolysis Bullosa took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dabocemagene autoficel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Dabocemagene autoficel overview
FCX-007 is under development for the treatment of recessive dystrophic epidermolysis bullosa. The drug candidate is formulated as suspension and is administered through intradermal route. The drug candidate is an autologous human dermal transduced with a lentiviral vector that acts by targeting COL7A1. The gene therapy is developed based on UltraVector platform. It was also under development for the treatment of cutaneous eosinophilias.
Castle Creek Biosciences overview
Castle Creek Biosciences is a privately held, clinical-stage cell and gene therapy company. The company is focused on developing and commercializing innovative personalized therapies for patients living with underserved disorders with high unmet medical needs. The company is headquartered in Chester, Pennsylvania, the US.
Quick View Dabocemagene autoficel LOA Data
|Highest Development Stage|